ED90 of 0.75% Bupivacaine for Bilateral Tubal Ligation (BTL)

• Status: Not yet recruiting
• Trial end date: 2023-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine the dose of bupivacaine that provides effective pain management in 90% (ED90) of patients undergoing bilateral tubal ligation. This will guide anesthesiologists on the most effective dose to minimize intraoperative pain during this procedure. The goal is to make women as comfortable as possible when they undergo this procedure while also minimizing the amount of time they are required to remain in the hospital afterwards for monitoring.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Duke University
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

• ≥ 18 years of age

• American Society of Anesthesiology class II or III

• bilateral tubal ligation

Exclusion Criteria:

• patient refusal

• BMI ≥ 50 kg/m2

• American Society of Anesthesiology class IV or above

• contraindication to neuraxial anesthesia

• allergy to bupivacaine